Arrowhead Pharmaceuticals Prices $45 Million Private Offering

Home/Newsroom/

Arrowhead Pharmaceuticals Prices...

PASADENA, Calif.–(BUSINESS WIRE)–

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it

has priced a private offering of its common stock with gross proceeds

expected to be $45 million. The offering was priced at $5.90 per share.

Cantor Fitzgerald & Co. acted as sole placement agent for the offering.

Approximately 7.63 million shares of common stock are expected to be

issued at the closing of the offering. The offering is expected to close

on or about August 12, 2016, subject to the satisfaction of customary

closing conditions.

This press release shall not constitute an offer to sell or the

solicitation of an offer to buy these securities, nor shall there be any

offer, solicitation or sale of these securities in any jurisdiction in

which such offer, solicitation or sale would be unlawful.

The securities to be sold in the private placement have not been

registered under the Securities Act of 1933, as amended (the “Securities

Act”), or any state or other jurisdiction’s securities laws, and may not

be offered or sold in the United States absent registration or an

applicable exemption from the registration requirements of the

Securities Act and applicable state or other jurisdictions’ securities

laws. The Company has agreed to file a registration statement with the

Securities and Exchange Commission registering the resale of the shares

of common stock to be issued and sold in the private placement.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable

diseases by silencing the genes that cause them. Using a broad portfolio

of RNA chemistries and efficient modes of delivery, Arrowhead therapies

trigger the RNA interference mechanism to induce rapid, deep, and

durable knockdown of target genes. RNA interference, or RNAi, is a

mechanism present in living cells that inhibits the expression of a

specific gene, thereby affecting the production of a specific protein.

Arrowhead’s RNAi-based therapeutics leverage this natural pathway of

gene silencing. The company’s pipeline includes ARC-520 and ARC-521 for

chronic hepatitis B virus infection, ARC-AAT for liver disease

associated with alpha-1 antitrypsin deficiency, ARC-F12 for hereditary

angioedema and thromboembolic disorders, ARC-LPA for cardiovascular

disease, and ARC-HIF2 for renal cell carcinoma.

For more information, please visit www.arrowheadpharma.com,

or follow us on Twitter @ArrowheadPharma.

To be added to the Company’s email list and receive news directly,

please visit http://ir.arrowheadpharma.com/alerts.cfm.

Safe Harbor Statement under the Private Securities Litigation Reform

Act:

This news release contains forward-looking statements within the

meaning of the “safe harbor” provisions of the Private Securities

Litigation Reform Act of 1995. These statements are based upon our

current expectations and speak only as of the date hereof. Our actual

results may differ materially and adversely from those expressed in any

forward-looking statements as a result of various factors and

uncertainties, including our ability to finance our operations, the

future success of our scientific studies, our ability to successfully

develop drug candidates, the timing for starting and completing clinical

trials, rapid technological change in our markets, and the enforcement

of our intellectual property rights. Our most recent Annual Report on

Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of

the important risk factors that may affect our business, results of

operations and financial condition. We assume no obligation to update or

revise forward-looking statements to reflect new events or circumstances.

DYNAMIC POLYCONJUGATES is a trademark of Arrowhead

Pharmaceuticals, Inc.

Source: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
ir@arrowheadpharma.com
or
Investor

Relations:
The Trout Group
Chad Rubin
646-378-2947
ir@arrowheadpharma.com
or
Media:
Russo

Partners
Matt Middleman, M.D.
212-845-4272
matt.middleman@russopartnersllc.com

Source: Arrowhead Pharmaceuticals Inc.

News Provided by Acquire Media